Jay Mary Rose‐Roque
Research Subjects
Jay Mary Rose‐Roque has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Shinnette Lumame
Abu Dhabi Stem Cells Center (ADSCC) Abu Dhabi UAE
8 shared publications - Yandy Marx Castillo-Aleman
Abu Dhabi Stem Cells Center (ADSCC), Abu Dhabi, United Arab Emirates; Yas Clinic Khalifa City (YCKC) Hospital, Abu Dhabi, United Arab Emirates
8 shared publications - Marlene Cato
Abu Dhabi Stem Cells Center (ADSCC) Abu Dhabi UAE
7 shared publications - Antonio Alfonso Bencomo-Hernandez
Abu Dhabi Stem Cells Center (ADSCC), United Arab Emirates
6 shared publications - Carlos Agustin Villegas‐Valverde
Research and Development Abu Dhabi Stem Cells Center Abu Dhabi UAE
6 shared publications - Yendry Ventura-Carmenate
Research and Development Abu Dhabi Stem Cells Center Abu Dhabi UAE
6 shared publications
Latest Publications
- 30 August 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (5) , e70174
Predicting Non‐Target Neutrophil Collection During HPC (A): Implications for Research Protocols in Apheresis
Neutrophils are unintentionally co‐collected during HPC(A) procedures using mononuclear cell collection protocols. Although non‐target granulocyte co‐collection is generally clinically acceptable, excessive neutrophil content may compromise certain translational research applications. This study aimed to develop a predictive model for neutrophil yield during routine HPC(A). A retrospective single‐center analysis of 377 HPC(A) procedures performed between January 2023 and April 2026 was conducted. Donor demographics, hematological parameters, procedural characteristics, and collection efficiency (CE) metrics were analyzed. Correlations between CE 1 and CE 2 were evaluated using Spearman's rank correlation coefficient. A multivariable linear regression model incorporating pre‐apheresis neutrophil count, processed blood volume (pBV), and neutrophil CE 1 was developed to predict neutrophil apheresis yield. Model performance was assessed using R 2 , RMSE, MAE, Bland–Altman analysis, and 5‐fold cross‐validation. Strong positive correlations were observed between CE 1 and CE 2 for both CD34 + cells ( ρ = 0.836, p < 0.0001) and neutrophils ( ρ = 0.865, p < 0.0001). In contrast, the multivariate regression model demonstrated only modest predictive performance for neutrophil yield ( R 2 = 0.198). Compared with the conventional fixed CE 1 approach, the regression‐based model showed lower RMSE, reduced systematic bias, and improved agreement between predicted and observed neutrophil yields on Bland–Altman analysis. Neutrophil yield during HPC(A) can be estimated using a regression model that integrates pre‐apheresis neutrophil count, pBV, and CE 1 . Although predictive performance remains modest, regression‐based approaches improve estimation accuracy compared with simplified fixed CE models and may support procedural planning and translational research applications involving non‐target granulocyte co‐collection in HPC(A) products.
- 30 August 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (5) , e70174
Predicting Non‐Target Neutrophil Collection During HPC (A): Implications for Research Protocols in Apheresis
Neutrophils are unintentionally co‐collected during HPC(A) procedures using mononuclear cell collection protocols. Although non‐target granulocyte co‐collection is generally clinically acceptable, excessive neutrophil content may compromise certain translational research applications. This study aimed to develop a predictive model for neutrophil yield during routine HPC(A). A retrospective single‐center analysis of 377 HPC(A) procedures performed between January 2023 and April 2026 was conducted. Donor demographics, hematological parameters, procedural characteristics, and collection efficiency (CE) metrics were analyzed. Correlations between CE 1 and CE 2 were evaluated using Spearman's rank correlation coefficient. A multivariable linear regression model incorporating pre‐apheresis neutrophil count, processed blood volume (pBV), and neutrophil CE 1 was developed to predict neutrophil apheresis yield. Model performance was assessed using R 2 , RMSE, MAE, Bland–Altman analysis, and 5‐fold cross‐validation. Strong positive correlations were observed between CE 1 and CE 2 for both CD34 + cells ( ρ = 0.836, p < 0.0001) and neutrophils ( ρ = 0.865, p < 0.0001). In contrast, the multivariate regression model demonstrated only modest predictive performance for neutrophil yield ( R 2 = 0.198). Compared with the conventional fixed CE 1 approach, the regression‐based model showed lower RMSE, reduced systematic bias, and improved agreement between predicted and observed neutrophil yields on Bland–Altman analysis. Neutrophil yield during HPC(A) can be estimated using a regression model that integrates pre‐apheresis neutrophil count, pBV, and CE 1 . Although predictive performance remains modest, regression‐based approaches improve estimation accuracy compared with simplified fixed CE models and may support procedural planning and translational research applications involving non‐target granulocyte co‐collection in HPC(A) products.
- 29 May 2026
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 65 (4) , 104467
Platelet loss during hematopoietic progenitor cell apheresis: Predictive factors and clinical implications in G-CSF-mobilized donors
- 29 May 2026
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 65 (4) , 104467
Platelet loss during hematopoietic progenitor cell apheresis: Predictive factors and clinical implications in G-CSF-mobilized donors
- 27 March 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70118
Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells
Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).
- 27 March 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2) , e70118
Citrate Versus Citrate–Heparin Anticoagulation in HPC (A): Comparative Effects on Intra‐Apheresis Mobilization of CD34 + Hematopoietic Progenitor Cells
Successful hematopoietic stem cell transplantation relies on the collection of a sufficient number of CD34 + hematopoietic progenitor cells (HPCs). While acid citrate dextrose solution A (ACD‐A) is a common anticoagulant (AC) for HPC apheresis [HPC(A)], recent evidence suggests that concomitant heparin may enhance intra‐apheresis recruitment (IAR) of CD34 + cells and improve collection efficiency. This study aimed to compare citrate‐only and citrate–heparin protocols in routine HPC(A) procedures, with a focus on their effects on IAR and efficiency outcomes. A retrospective analysis was performed on 266 HPC(As) from 193 apheresis donors in autologous and allogeneic settings. Donor demographics, procedural parameters, and collection outcomes were compared between the ACD‐A–only and ACD‐A plus heparin protocols. The study endpoints included apheresis yield (AY/kg), collection efficiencies (CE 1 , CE 2 , and cruCE), recruitment ratio (RR), and performance ratio (PR). Statistical analyses included Mann–Whitney U tests, effect sizes, and partial least squares (PLS) regression. Heparinized procedures demonstrated higher processed total blood volume ratios, lower AC volumes, and superior outcomes across CE 1 (83.8% vs. 72.5%, p = 0.00027), CE 2 (70.8% vs. 64.2%, p = 0.0055), cruCE (77.0% vs. 72.4%, p < 0.0001), RR (2.3 vs. 1.7, p < 0.0001), PR (239.3% vs. 208.2%, p < 0.0001), and AY/kg (6.75 vs. 5.23 × 10 6 CD34 + cells/kg, p = 0.0025). The effect size and PLS analyses confirmed the contribution of heparin as an adjunct AC enhancing multiple apheresis outcomes. In summary, citrate–heparin anticoagulation was found to be a feasible strategy that improved key collection efficiency and IAR metrics during HPC(A).
- 26 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2)
A Practical Method for Inline‐To‐Offline Conversion in Extracorporeal Photopheresis
Extracorporeal photopheresis (ECP) is an established immunomodulatory therapy that is traditionally delivered using either “inline” systems, which integrate mononuclear cell (MNC) collection, photoactivation, and reinfusion, or “offline” platforms that allow greater processing flexibility but require dedicated irradiation equipment. Access to standalone UVA irradiators may be limited in clinical and research settings where cryopreservation of ECP‐treated cells is required. In this study, we describe a practical hybrid approach that adapts the inline Amicus Blue Photopheresis System into an inline‐to‐offline workflow, enabling larger total blood volume processing, partial reinfusion, and cryopreservation of photoactivated MNCs. Using a fixed 200‐mL MNC collection, followed by standard 8‐methoxypsoralen administration and UVA irradiation, 50 mL was reinfused inline, while the remaining product was aliquoted for offline cryopreservation. This method has been implemented in the OPERA clinical trial (NCT05413005) and preserves procedural safety, product integrity, and operational simplicity. In summary, this approach enables offline capabilities within an inline ECP framework without requiring an independent UVA irradiator and expands flexibility for clinical programs and translational research. Trial Registration: NCT05413005.
- 26 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (2)
A Practical Method for Inline‐To‐Offline Conversion in Extracorporeal Photopheresis
Extracorporeal photopheresis (ECP) is an established immunomodulatory therapy that is traditionally delivered using either “inline” systems, which integrate mononuclear cell (MNC) collection, photoactivation, and reinfusion, or “offline” platforms that allow greater processing flexibility but require dedicated irradiation equipment. Access to standalone UVA irradiators may be limited in clinical and research settings where cryopreservation of ECP‐treated cells is required. In this study, we describe a practical hybrid approach that adapts the inline Amicus Blue Photopheresis System into an inline‐to‐offline workflow, enabling larger total blood volume processing, partial reinfusion, and cryopreservation of photoactivated MNCs. Using a fixed 200‐mL MNC collection, followed by standard 8‐methoxypsoralen administration and UVA irradiation, 50 mL was reinfused inline, while the remaining product was aliquoted for offline cryopreservation. This method has been implemented in the OPERA clinical trial (NCT05413005) and preserves procedural safety, product integrity, and operational simplicity. In summary, this approach enables offline capabilities within an inline ECP framework without requiring an independent UVA irradiator and expands flexibility for clinical programs and translational research. Trial Registration: NCT05413005.
- 14 January 2026
- Published by Wiley in Therapeutic Apheresis and Dialysis
Plasma Separation Efficiency in Double Filtration Plasmapheresis: A Retrospective Study of Patients With Hyperlipidemia
Background: Double filtration plasmapheresis (DFPP) is a membrane‐based apheresis technique that separates plasma components using two sequential filters; it is commonly used to remove high‐molecular‐weight substances across various indications. While various metrics such as “plasma removal efficiency” are well established in therapeutic plasma exchange, “plasma separation efficiency” (PSE) remains unreported in DFPP. This study aims to evaluate PSE across DFPP sessions performed with plasma filters of different pore sizes. Materials and Methods: A retrospective study of DFPP procedures performed in patients with hyperlipidemia at a single center between April and July 2025 was conducted. Patient demographics, laboratory values, and procedural parameters were collected. PSE was calculated with and without hematocrit (HCT) adjustment (PSE 1 and PSE 2 ). Associations with procedural variables were assessed using paired tests and multivariate linear regression. Results: A total of 42 DFPPs were performed in 19 patients using the Inuspheresis system, alternating two plasma fractionators (DFPP‐1 and DFPP‐2 with large and small pore size, respectively). PSE 2 and PSE 1 declined significantly from DFPP‐1 to DFPP‐2 ( p = 0.0002 and p = 0.0014, respectively), with Cohen's d indicating large and moderate‐to‐large effect sizes. DFPP also resulted in significant reductions in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), and C‐reactive protein. Multivariate models showed that the plasma separation rate and HCT shifts were significantly associated with PSE 2 and PSE 1 during DFPP‐2 but not during DFPP‐1. Conclusions: PSE is a reproducible parameter influenced by membrane pore size and procedural factors. Incorporating PSE monitoring, particularly with HCT adjustment, may support optimization of individualized DFPP protocols in routine apheresis practice.
- 14 January 2026
- Published by Wiley in Therapeutic Apheresis and Dialysis
Plasma Separation Efficiency in Double Filtration Plasmapheresis: A Retrospective Study of Patients With Hyperlipidemia
Background: Double filtration plasmapheresis (DFPP) is a membrane‐based apheresis technique that separates plasma components using two sequential filters; it is commonly used to remove high‐molecular‐weight substances across various indications. While various metrics such as “plasma removal efficiency” are well established in therapeutic plasma exchange, “plasma separation efficiency” (PSE) remains unreported in DFPP. This study aims to evaluate PSE across DFPP sessions performed with plasma filters of different pore sizes. Materials and Methods: A retrospective study of DFPP procedures performed in patients with hyperlipidemia at a single center between April and July 2025 was conducted. Patient demographics, laboratory values, and procedural parameters were collected. PSE was calculated with and without hematocrit (HCT) adjustment (PSE 1 and PSE 2 ). Associations with procedural variables were assessed using paired tests and multivariate linear regression. Results: A total of 42 DFPPs were performed in 19 patients using the Inuspheresis system, alternating two plasma fractionators (DFPP‐1 and DFPP‐2 with large and small pore size, respectively). PSE 2 and PSE 1 declined significantly from DFPP‐1 to DFPP‐2 ( p = 0.0002 and p = 0.0014, respectively), with Cohen's d indicating large and moderate‐to‐large effect sizes. DFPP also resulted in significant reductions in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), and C‐reactive protein. Multivariate models showed that the plasma separation rate and HCT shifts were significantly associated with PSE 2 and PSE 1 during DFPP‐2 but not during DFPP‐1. Conclusions: PSE is a reproducible parameter influenced by membrane pore size and procedural factors. Incorporating PSE monitoring, particularly with HCT adjustment, may support optimization of individualized DFPP protocols in routine apheresis practice.
- 29 September 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (5) , e70060
Double Filtration Plasmapheresis for Environmental Toxin Removal: A Case Series of Patients With Hyperlipoproteinemia(a)
Double filtration plasmapheresis (DFPP) is a promising method for removing environmental toxins, but comparative data on toxin‐specific removal patterns remain limited. This study investigates the removal effectiveness of various pollutants in patients with hyperlipoproteinemia(a) undergoing DFPP. We retrospectively analyzed procedures performed using the Inuspheresis System with two filters with differing pore sizes. We assessed the clearance of heavy metals, volatile organic compounds, and organic pollutants by calculating the “ redistribution ratio ” (RR) and the percentage of captured analyte (CA). Analytes with large volumes of distribution and low protein binding, such as toluene, methyl isobutyl ketone, and barium, showed high rebound (RR: 1.95, 1.31, and 1.97, respectively), suggesting redistribution from peripheral compartments. Moderate rebound was observed for partially protein‐bound toxins, including PCB 153 (0.76), PCB 138 (0.74), and hexachlorobenzene (0.66). Low or negative RRs were seen with arsenic (−0.49), mercury (−0.05), and cobalt (0.08), likely reflecting limited redistribution. High CA values were recorded for lipophilic, protein‐bound toxins such as PCBs and p,p′‐DDE. Herein, we demonstrate that DFPP is effective in removing environmental toxins from the human body. The pharmacokinetic properties of each compound are key determinants of DFPP effectiveness and may help guide the development of personalized detoxification strategies to optimize its clinical use.
- 29 September 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (5) , e70060
Double Filtration Plasmapheresis for Environmental Toxin Removal: A Case Series of Patients With Hyperlipoproteinemia(a)
Double filtration plasmapheresis (DFPP) is a promising method for removing environmental toxins, but comparative data on toxin‐specific removal patterns remain limited. This study investigates the removal effectiveness of various pollutants in patients with hyperlipoproteinemia(a) undergoing DFPP. We retrospectively analyzed procedures performed using the Inuspheresis System with two filters with differing pore sizes. We assessed the clearance of heavy metals, volatile organic compounds, and organic pollutants by calculating the “ redistribution ratio ” (RR) and the percentage of captured analyte (CA). Analytes with large volumes of distribution and low protein binding, such as toluene, methyl isobutyl ketone, and barium, showed high rebound (RR: 1.95, 1.31, and 1.97, respectively), suggesting redistribution from peripheral compartments. Moderate rebound was observed for partially protein‐bound toxins, including PCB 153 (0.76), PCB 138 (0.74), and hexachlorobenzene (0.66). Low or negative RRs were seen with arsenic (−0.49), mercury (−0.05), and cobalt (0.08), likely reflecting limited redistribution. High CA values were recorded for lipophilic, protein‐bound toxins such as PCBs and p,p′‐DDE. Herein, we demonstrate that DFPP is effective in removing environmental toxins from the human body. The pharmacokinetic properties of each compound are key determinants of DFPP effectiveness and may help guide the development of personalized detoxification strategies to optimize its clinical use.
- 20 July 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (4) , e70046
The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC(A) Collections
The hematopoietic progenitor cell apheresis [HPC(A)] is a cornerstone of stem cell transplantation. While multiple apheresis sessions are common in clinical practice, few studies have examined the procedural variability within the same donor across consecutive collections. This study aims to compare changes in the efficiency metrics between the first and second HPC(A) procedures. A retrospective analysis was conducted on paired HPC(A) procedures performed on the same donor between January 2023 and May 2025 at the Abu Dhabi Stem Cells Center. The predefined parameters, including the collection efficiencies (CE1, CE2, cruCE), performance ratio (PR), and total volume processed (TVP), were compared using the Wilcoxon signed‐rank tests. Effect sizes were calculated using Cohen's r, and associations between variables were assessed using the Spearman correlation. Of the 215 procedures screened, 90 met the inclusion criteria. Despite similar preapheresis CD34+ cell counts and flow rates, second‐day procedures demonstrated significantly improved CE1, CE2, and PR, with lower TVP. A large effect size was observed for the TVP/total blood volume (TBV) ratio (r = 0.63), and moderate‐to‐large effect sizes for CE2 (r = 0.41), PR (r = 0.47), and CE1 (r = 0.47). CE1 and CE2 correlated strongly with PR across both sessions, while CE2 correlated positively with TVP/TBV on day 1 (ρ = 0.47) and negatively on day 2 (ρ = −0.40). Second‐day HPC(A) sessions yielded superior efficiency despite reduced volume, supporting the value of individualized collection planning. These “day two advantages” may inform refinements in yield prediction and highlight the need for prospective studies to optimize apheresis strategies.
- 20 July 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (4) , e70046
The Day Two Advantage: A Retrospective Paired Analysis of Consecutive HPC(A) Collections
The hematopoietic progenitor cell apheresis [HPC(A)] is a cornerstone of stem cell transplantation. While multiple apheresis sessions are common in clinical practice, few studies have examined the procedural variability within the same donor across consecutive collections. This study aims to compare changes in the efficiency metrics between the first and second HPC(A) procedures. A retrospective analysis was conducted on paired HPC(A) procedures performed on the same donor between January 2023 and May 2025 at the Abu Dhabi Stem Cells Center. The predefined parameters, including the collection efficiencies (CE1, CE2, cruCE), performance ratio (PR), and total volume processed (TVP), were compared using the Wilcoxon signed‐rank tests. Effect sizes were calculated using Cohen's r, and associations between variables were assessed using the Spearman correlation. Of the 215 procedures screened, 90 met the inclusion criteria. Despite similar preapheresis CD34+ cell counts and flow rates, second‐day procedures demonstrated significantly improved CE1, CE2, and PR, with lower TVP. A large effect size was observed for the TVP/total blood volume (TBV) ratio (r = 0.63), and moderate‐to‐large effect sizes for CE2 (r = 0.41), PR (r = 0.47), and CE1 (r = 0.47). CE1 and CE2 correlated strongly with PR across both sessions, while CE2 correlated positively with TVP/TBV on day 1 (ρ = 0.47) and negatively on day 2 (ρ = −0.40). Second‐day HPC(A) sessions yielded superior efficiency despite reduced volume, supporting the value of individualized collection planning. These “day two advantages” may inform refinements in yield prediction and highlight the need for prospective studies to optimize apheresis strategies.
- 10 July 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (4) , e70045
Green Plasma in Extracorporeal Photopheresis: A Case Report in Overlap Chronic GvHD
We report the case of a 50‐year‐old male with peripheral T‐cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation and developed overlap chronic graft‐versus‐host disease (ocGvHD) requiring extracorporeal photopheresis (ECP). His clinical presentation included a maculopapular rash with jaundice, hepatosplenomegaly, hyperbilirubinemia, and elevated liver enzymes. Liver biopsy findings were not consistent with GvHD or lymphoma but were suggestive of drug‐induced hepatitis. ECP was initiated using the Therakos CellEx Photopheresis System. During the initial sessions, dark green plasma discoloration was observed, accompanied by multiple plasma/red blood cell interface‐related procedural alarms. These challenges were managed through various operator adjustments, and the procedures remained safe and effective. Over four ECP sessions, both the discoloration and opacity of the plasma progressively improved, in parallel with declining liver enzyme levels and a reduction in procedural alarms. This temporal association between hepatic recovery and improved interface stability during ECP has not been previously described in the context of ocGvHD. Although dark green plasma is an uncommon finding in this setting, it should prompt evaluation for underlying hepatic dysfunction and timely management of plasma/red blood cell interface issues to ensure safe and effective ECP delivery.
- 10 July 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (4) , e70045
Green Plasma in Extracorporeal Photopheresis: A Case Report in Overlap Chronic GvHD
We report the case of a 50‐year‐old male with peripheral T‐cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation and developed overlap chronic graft‐versus‐host disease (ocGvHD) requiring extracorporeal photopheresis (ECP). His clinical presentation included a maculopapular rash with jaundice, hepatosplenomegaly, hyperbilirubinemia, and elevated liver enzymes. Liver biopsy findings were not consistent with GvHD or lymphoma but were suggestive of drug‐induced hepatitis. ECP was initiated using the Therakos CellEx Photopheresis System. During the initial sessions, dark green plasma discoloration was observed, accompanied by multiple plasma/red blood cell interface‐related procedural alarms. These challenges were managed through various operator adjustments, and the procedures remained safe and effective. Over four ECP sessions, both the discoloration and opacity of the plasma progressively improved, in parallel with declining liver enzyme levels and a reduction in procedural alarms. This temporal association between hepatic recovery and improved interface stability during ECP has not been previously described in the context of ocGvHD. Although dark green plasma is an uncommon finding in this setting, it should prompt evaluation for underlying hepatic dysfunction and timely management of plasma/red blood cell interface issues to ensure safe and effective ECP delivery.